Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has announced that it has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its WELLlife COVID-19/Influenza A&B Home Test. This triplex test kit, available in an over-the-counter (OTC) version, is designed to detect COVID-19, influenza A virus, and influenza B virus.
The authorization allows the product to be sold through various retail channels in the US, including e-commerce platforms, pharmacies, and supermarkets, enabling consumers to purchase the home test kit without a prescription. This move is expected to expand the accessibility of COVID-19 and influenza testing, facilitating faster and more convenient diagnosis for the US market.- Flcube.com
